Precision gene therapies for heart failure

AaviGen is at the forefront of developing innovative gene therapies specifically targeting cardiac diseases, particularly heart failure. The company utilizes organ-specific Adeno-Associated Viral (AAV) vectors, which are engineered through their proprietary next-CAP platform. This platform allows AaviGen to create a diverse library of AAV vectors tailored for cardiac applications, ensuring high specificity and safety in gene delivery. By leveraging extensive molecular and translational research, AaviGen aims to address the underlying cellular and molecular dysfunctions associated with heart failure, which affects millions globally. Their approach focuses on correcting the aberrant processes that lead to heart failure, thereby improving patient outcomes.

The therapeutic pipeline at AaviGen is designed to tackle the complexities of heart failure by targeting critical molecular pathways involved in cardiac function. Their gene therapy strategies aim to restore normal activity in the heart's molecular networks, enhancing contractile performance and energy metabolism. AaviGen's research emphasizes the importance of understanding the pathophysiology of heart failure, allowing for the development of targeted interventions that can reverse the detrimental effects of the disease. By focusing on specific therapeutic targets, AaviGen is poised to revolutionize cardiovascular care and provide much-needed solutions for patients suffering from heart failure.

Germany

AaviGen GmbH is a biotechnology start-up located in Heidelberg, Germany. Our primary purpose is the development and commercialization of precision gene therapies for cardiovascular and cardiopulmonary diseases. Our business model builds on the success of the InoCard GmbH, a predecessor that was acquired by uniQure N.V. and subsequently entered into a development alliance with Bristol-Myers-Squibb.

Please find our imprint ("Impressum") and data privavy statement ("Datenschutzerklärung") at https://aavigen.com/content/imprint.html and https://aavigen.com/content/privacy.html

AaviGen

Company Details